The effect of AP2M1 was investigated at a cellular resolution using single‐cell RNA sequencing (scRNA‐seq) technology, with validation achieved through in vitro assays, a zebrafish model system, and clinical samples from AML patients. This evidence concerns the gene AP2M1 and acute myeloid leukemia.